RESUMO
BACKGROUND: Aqueous shunts are employed for intraocular pressure (IOP) control in primary and secondary glaucomas that fail medical, laser, and other surgical therapies. OBJECTIVES: This review compares aqueous shunts for IOP control and safety. SEARCH STRATEGY: We searched CENTRAL, MEDLINE, PubMed, EMBASE, NRR all in January 2006, LILACS to February 2004 and reference lists of included trials. SELECTION CRITERIA: We included all randomized and quasi-randomized trials in which one arm of the study involved shunts. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data for included studies and a third adjudicated discrepancies. We contacted investigators for missing information. We used fixed-effect models and summarized continuous outcomes using mean differences. MAIN RESULTS: We included fifteen trials with a total of 1153 participants with mixed diagnoses. Five studies reported details sufficient to verify the method of randomization but only two had adequate allocation concealment. Data collection and follow-up times were variable.Meta-analysis of two trials comparing Ahmed implant with trabeculectomy found trabeculectomy resulted in lower mean IOPs 11 to 13 months later (mean difference 3.81 mm Hg, 95% CI 1.94 to 5.69 mm Hg). Meta-analysis of two trials comparing double-plate Molteno implant with the Schocket shunt was not done due to substantial heterogeneity. One study comparing ridged with standard double-plate Molteno implants found no clinically significant differences in outcome. Two trials investigating the effectiveness of adjunctive mitomycin (MMC) with the Molteno and Ahmed implants found no evidence of benefit with MMC. Two trials that investigated surgical technique variations with the Ahmed found no benefit with partial tube ligation or excision of Tenon's capsule. One study concluded there were outcome advantages with a double versus a single-plate Molteno implant and one trial comparing the 350 mm(2) and 500 mm(2) Baerveldt shunts found no clinically significant advantage of the larger device but neither of these trials included all patients randomized. One study suggested improved clinical outcome when MMC was employed with a newly described shunt including ultrasound supporting the conclusion. One small study did not demonstrate an outcome advantage to systemic steroid use postoperatively with single-plate Molteno shunts. One study comparing endocyclophotocoagulation (ECP) with Ahmed implant in complicated glaucomas found no evidence of better IOP control with Ahmed implant over ECP. AUTHORS' CONCLUSIONS: Relatively few randomized trials have been published on aqueous shunts and methodology and data quality among them is poor. To date there is no evidence of superiority of one shunt over another.
Assuntos
Implantes para Drenagem de Glaucoma , Glaucoma/cirurgia , Pressão Intraocular , Extração de Catarata , Implantes para Drenagem de Glaucoma/efeitos adversos , Humanos , Implantes de Molteno/efeitos adversos , Hipertensão Ocular/cirurgia , Ensaios Clínicos Controlados Aleatórios como Assunto , TrabeculectomiaRESUMO
AIM: This study examines the changes in axial length (AL) after trabeculectomy and glaucoma drainage device (GDD) surgery and enabled an equation to be derived allowing prediction of AL change after filtering surgery. METHODS: This was a prospective, interventional case series from the Glaucoma Service of the Doheny Eye Institute. PATIENT POPULATION: One eye of 39 patients undergoing trabeculectomy and 22 undergoing Baerveldt tube shunt implantation for uncontrolled glaucoma. INTERVENTION: These patients had AL measurements by non-contact, partial coherence interferometry preoperatively, at 1 week, 1 month, and >3 months after surgery. MAIN OUTCOME MEASURES: Axial length and intraocular pressure were compared at preoperative and postoperative visits. Postoperative intraocular pressure (IOP) was categorised as hypotonous (0-4 mm Hg), low (5-9), normal (10-17), and high (18 or more). RESULTS: There was a statistically significant reduction in IOP after 3 months of -12.8 (SD 1.5) mm Hg following trabeculectomy (p<0.001), and -10.7 (1.9) mm Hg after GDD (p<0.001). There was a statistically significant reduction in AL, which was similar after trabeculectomy and GDD at all time points (p<0.001), of -0.15 (0.03) and -0.21 (0.04) mm (1 week), -0.18 (0.02) and -0.10 (0.02) mm (1 month), and -0.16 (0.03) and -0.15 (0.03) mm (3 months). At 3 months or later the AL reduction was related to postoperative IOP and to the amount of IOP reduction (p<0.05, stepwise multiple regression). 10.2% (4/39) of trabeculectomy patients had hypotony after 3 months, with a mean AL reduction (-0.39 (0.11)) that was statistically significantly lower (p<0.01) than the other trabeculectomy eyes (-0.14 (0.15)). CONCLUSIONS: There is a small but statistically significant decrease in AL after both trabeculectomy and GDD surgery, greater in eyes that are hypotonous after surgery. The authors suggest that AL reduction can be predicted after 3 months by the formula: AL reduction (mm) = -199+0.006 x IOP reduction+0.008 x final IOP.
Assuntos
Olho/patologia , Implantes para Drenagem de Glaucoma , Glaucoma/cirurgia , Trabeculectomia/métodos , Idoso , Feminino , Cirurgia Filtrante/métodos , Glaucoma/patologia , Glaucoma/fisiopatologia , Humanos , Pressão Intraocular/fisiologia , Masculino , Período Pós-Operatório , Estudos Prospectivos , Resultado do TratamentoRESUMO
PURPOSE: To compare the intraocular pressure (IOP) lowering effect of concomitant administration of 0.5% timolol and 2% dorzolamide and a fixed combination dorzolamide-timolol (Cosopt) To critically evaluate discrepancies between phase 3 clinical trials and prior replacement studies. DESIGN: A prospective, randomized, controlled clinical trial and a prospective, non-randomized comparative replacement trial. PARTICIPANTS/INTERVENTIONS: In a national multicentre trial, 131 patients were randomized to dorzolamide-timolol or a topical carbonic anhydrase inhibitor (CAI) and non-selective beta-blocker following a 1-month run-in using the separate components. Peak (maximal drug effect) and trough (minimal drug effect) IOPs were measured at baseline and 1 month after treatment. The replacement therapy study enrolled 404 consecutive glaucoma patients using a non-selective beta-blocker and dorzolamide and changed treatment to the fixed combination. Mean IOPs at the same time of day were compared before and 1 month after changeover. MAIN OUTCOME MEASURE: The main outcome measure was IOP, comparing baseline and on-therapy measurements at study conclusion between the two arms of the randomized trial and before and after switching therapy in the replacement trial. RESULTS: In the randomized trial, the mean baseline peak and trough IOPs were 18.4 and 21.0 mmHg in the group randomized to combination therapy and 17.6 and 19.8 mmHg in the dual drug group. After randomization and treatment for four weeks, the peak and trough IOPs were 17.6 and 19.5 mmHg in the combination group and 17.3 and 19.0 mmHg in the concomitant group. The percentage change in IOP was -3.2% at peak and -6.5% at trough for the combination and -0.3 and -3.2% for the concomitant group. These differences did not show statistical significance. In the replacement study, mean baseline IOP was 19.4 mmHg. Four weeks after initiation of treatment on the fixed combination, a significant additional IOP reduction of 1.7 mmHg (-8.8%) was observed (P < 0.0001). Overall, 81% of eyes exhibited equal or lower IOP on the fixed combination compared with concomitant therapy. CONCLUSION: The results of the randomized trial indicate that the fixed combination dorzolamide-timolol (Cosopt) was as effective as its components in controlling IOP, confirming results seen in phase 3 clinical trials. However, in the replacement study, utilization of the combination drug offered a statistically significant additional IOP reduction (P < 0.0001), which duplicates results from previous replacement studies.
Assuntos
Anti-Hipertensivos/uso terapêutico , Inibidores da Anidrase Carbônica/uso terapêutico , Glaucoma/tratamento farmacológico , Pressão Intraocular/efeitos dos fármacos , Sulfonamidas/uso terapêutico , Tiofenos/uso terapêutico , Timolol/uso terapêutico , Idoso , Combinação de Medicamentos , Quimioterapia Combinada , Feminino , Humanos , Masculino , Estudos ProspectivosRESUMO
PURPOSE: This experimental study was conducted to report perfusion characteristics of small diameter, cylindrical aqueous shunts in normal rabbit eyes and to test the hypothesis that decreasing bleb diameter would decrease capsular fibrosis, as evidenced by a thinner capsule forming around the implant. These two properties increase hydraulic conductivity of the fibrous membrane forming around the device, resulting in a more effective filtering shunt. METHODS: Cylindrical latex tubes with the distal portion of the sidewall removed were implanted under the conjunctiva. The proximal, intact end of tubing was inserted into the anterior chamber and ligated to prevent hypotony. The ligature was released after 1 week to inflate the bleb. Animals were again anesthetized at 6 or 12 weeks after ligature release and in vivo perfusion experiments conducted using a miniperfusion system and a water manometer. Perfusion of the implant with latex microspheres was performed before the animals were killed. Capsule diameters were measured in situ using calipers under a dissecting microscope after excision of orbital tissues and before fixation for histologic study. Membrane hydraulic conductivity (outflow per unit membrane area at unitary pressure gradient, microL/min/mm2/mmHg) was calculated using data obtained during perfusion experiments and compared with results of other studies. Capsule thickness was measured histologically. RESULTS: Cylindrical filtration membranes with thin (15-20 microm) capsules formed around latex implants. Bleb diameters consistently measured 1 mm at all points along their length before formaldehyde fixation. Hydraulic conductivity was measured and found to be eight times higher than that reported for capsules around conventional implants. Decreased diameter (16:1 for Baerveldt and 13:1 for Molteno implants) produced a proportional decrease in surface tension on the wall. This resulted in decreased capsule thickness, from 222 microm for Baerveldt implants in rabbit eyes and from 150 microm for Molteno implants in monkey eyes to less than 20 microm for the shunting device studied here. CONCLUSION: As a consequence of Laplace's law, reduction in bleb diameter reduces surface tension on the bleb, reducing capsular fibrosis and consequently capsule thickness, thus increasing hydraulic conductivity. Increased hydraulic conductivity increases the effectiveness of the filtering surface. Cylindrical geometry allows reduced bleb volume yet maintains total surface area that is proportional to the length of the implant, which is unlimited and customizable for each eye by simply cutting the length of implant needed.
Assuntos
Humor Aquoso/metabolismo , Materiais Biocompatíveis , Cirurgia Filtrante/métodos , Implantes para Drenagem de Glaucoma , Látex , Animais , Fibrose/prevenção & controle , Pressão Intraocular , Coelhos , Esclera/patologiaRESUMO
OBJECTIVE: To report the longer term results of a randomized, clinical trial comparing the 350-mm2 and the 500-mm2 Baerveldt glaucoma implants. DESIGN: Extended follow-up on a randomized, controlled trial. PARTICIPANTS: Between March 1991 and April 1993, 107 patients with uncontrolled intraocular pressure (IOP) due to non-neovascular glaucoma associated with aphakia, pseudophakia, or failed filters were randomly assigned for surgical placement of either the 350-mm or the 500-mm2 Baerveldt implant at the Doheny Eye Institute. METHODS: A random-numbers table was used to assign each patient to one of the two groups. Preoperative IOPs and visual acuities were recorded. Clinical records were reviewed to ascertain postoperative IOPs, visual acuities, number of medications used, and implant-related complications that occurred throughout the follow-up period. MAIN OUTCOME MEASURES: Success was defined as IOP of 6 mmHg or greater and of 21 mmHg or less in two or more consecutive follow-up visits without further glaucoma surgery or loss of light perception attributable to glaucoma. RESULTS: The overall success rates were 87% for the 350-mm2 group and 70% for the 500-mm2 group (P = 0.05). Average follow-up was 37 months (range, 1-76 months) for the 350-mm2 group and 34 months (range, 5-77 months) for the 500-mm2 group. The life-table success rates declined over time for both implant groups, from a high of 98% for the 350-mm2 group and 92% for the 500-mm2 group at 1 year to a cumulative success rate of 79% for the 350-mm2 group and 66% for the 500-mm2 group at 5 years. Visual acuities were better or remained the same in 50% of the patients in the 350-mm2 group and 46% of those in the 500-mm2 group. Complications during the 5-year follow-up were also statistically similar. CONCLUSIONS: The longer term results show that the 350-mm2 Baerveldt implant is more successful than the 500-mm2 implant for overall IOP control. Interval comparisons indicate a higher rate of success for the 350-mm2 implant in the first, second, third, fourth, and fifth years of implantation. Visual acuities, implant-related complications, and average IOPs were statistically indistinguishable between the two groups.
Assuntos
Implantes para Drenagem de Glaucoma , Glaucoma/cirurgia , Pressão Intraocular , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Afacia Pós-Catarata/complicações , Criança , Feminino , Seguimentos , Glaucoma/etiologia , Glaucoma/fisiopatologia , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Implantação de Prótese , Pseudofacia/complicações , Estudos Retrospectivos , Acuidade VisualRESUMO
BACKGROUND AND OBJECTIVE: To investigate the outcome and complication rates of trabeculectomy following the combined use of intraoperative, topical 5-fluorouracil (5-FU) and low-dose, postoperative subconjunctival 5-FU injections. PATIENTS AND METHODS: Forty-one eyes of 41 patients with advanced, medically uncontrolled glaucoma underwent trabeculectomy with intraoperative episcleral application of 5-FU (50 mg/ml for 5 minutes). A variable number of subconjunctival 5-FU injections were administered postoperatively at the discretion of the operating surgeon. RESULTS: Six-, 12-, and 15-month life-table success rates (5 mm Hg < or = intraocular pressure [IOP < or = 21 mm Hg) were 100%, 97%, and 83%, respectively. Mean postoperative IOP was 12.1 +/- 4.3 mm Hg. An average of 2.2 +/- 1.6 (range 0 to 7) supplemental subconjunctival 5-FU injections were administered postoperatively. Corneal epithelial erosions developed in 7 (17%) of the eyes. Five of 7 patients who underwent subsequent surgical procedures maintained successful control of IOP at an average of 11.0 +/- 4.8 (range 5 to 16) months after the secondary surgery. CONCLUSION: Trabeculectomy with intraoperative 5-FU is effective in controlling IOP while possibly minimizing the need for frequent postoperative injections and the occurrence of corneal epitheliopathy.
Assuntos
Antimetabólitos Antineoplásicos/administração & dosagem , Fluoruracila/administração & dosagem , Glaucoma/cirurgia , Trabeculectomia , Adulto , Idoso , Idoso de 80 Anos ou mais , Glaucoma/tratamento farmacológico , Humanos , Pressão Intraocular , Período Intraoperatório , Pessoa de Meia-Idade , Estudos Retrospectivos , Esclera/efeitos dos fármacos , Resultado do Tratamento , Acuidade VisualRESUMO
PURPOSE: The purpose of the study was to define a newly recognized complication after glaucoma surgery and to recommend a therapeutic regimen. METHODS: Eighteen patients diagnosed initially as having aqueous misdirection after glaucoma surgery, but who subsequently were found by ultrasonography to have an annular peripheral choroidal detachment that resulted in secondary angle closure glaucoma, were studied. Ten of these patients were treated with topical cycloplegics and corticosteroids, and 8 were treated with drainage of suprachoroidal fluid. Outcomes of these two treatment methods were compared. RESULTS: Annular peripheral choroidal detachment reliably was diagnosed with ultrasonography. Of the variables studied, time elapsed before resolution of the annular peripheral choroidal detachment was noted to be statistically significant (P < 0.00005). Immediate resolution followed drainage of suprachoroidal fluid, whereas a mean of 19.6 days was required for resolution after medical therapy. CONCLUSIONS: Annular peripheral choroidal detachment should be considered in the differential diagnosis of a flat or shallow anterior chamber with normal or high intraocular pressure after glaucoma surgery. The diagnosis of annular peripheral choroidal detachment can be confirmed most reliably by ultrasonography. Medical therapy is as effective as is surgery, although a significantly longer time to resolution is required.
Assuntos
Humor Aquoso , Doenças da Coroide/etiologia , Glaucoma de Ângulo Fechado/etiologia , Glaucoma/cirurgia , Trabeculectomia/efeitos adversos , Adulto , Idoso , Idoso de 80 Anos ou mais , Doenças da Coroide/diagnóstico por imagem , Doenças da Coroide/terapia , Drenagem , Exsudatos e Transudatos , Feminino , Glaucoma de Ângulo Fechado/diagnóstico por imagem , Glaucoma de Ângulo Fechado/terapia , Glucocorticoides/uso terapêutico , Humanos , Pressão Intraocular , Masculino , Pessoa de Meia-Idade , Midriáticos/uso terapêutico , Soluções Oftálmicas , Complicações Pós-Operatórias , Prednisolona/uso terapêutico , Próteses e Implantes , Ultrassonografia , Acuidade VisualRESUMO
Raised intraocular pressure is a common and frequently serious complication of anterior uveitis. The milieu of inflammatory cells, the mediators they release, and the corticosteroid therapy used to treat the uveitis can participate in the pathogenesis of uveitic glaucoma. These factors alter the normal anatomic structure of the anterior chamber and angle, influencing aqueous production and outflow. These changes act to disrupt the homeostatic mechanisms of intraocular pressure control. Structural changes in the angle can be acute, such as in secondary angle closure with pupillary block glaucoma, or chronic, such as combined steroid-induced and secondary open angle glaucoma. Management of uveitic glaucoma may be difficult because of the numerous mechanisms involved in its pathogenesis. Diagnostic and therapeutic decisions are guided by careful delineation of the pathophysiology of each individual case. The goal of treatment is to minimize permanent structural alteration of aqueous outflow and to prevent damage to the optic nerve head. This article reviews the pathogenesis of uveitic glaucoma, with specific attention to etiology. Medical and surgical therapies are also discussed, with emphasis on the more recent developments in each category.
Assuntos
Glaucoma/complicações , Uveíte/complicações , Glaucoma/diagnóstico , Glaucoma/terapia , Humanos , Uveíte/diagnóstico , Uveíte/terapiaRESUMO
PURPOSE: To evaluate the potential value of obtaining follow-up stereoscopic photographs on glaucoma suspects in identifying progressive optic nerve damage. METHODS: Nineteen sets of stereoscopic optic disc photographs, reflecting one eye from each of 19 patients at two time points, were selected from the records of subjects enrolled in the Glaucoma Screening Study. By consensus, three experts judged 13 of these eyes to have progressive glaucomatous optic nerve damage. Four other ophthalmologists who were masked to the expert panel evaluation then assessed glaucomatous progression in the same eyes. They were asked to evaluate glaucomatous progression in three ways: first, by drawing the optic nerve head appearance from initial stereoscopic photographs and later comparing their own drawings to follow-up stereoscopic photographs; second, by comparing serial stereoscopic photographs directly; and third, by comparing drawings of the optic nerve head made by another examiner to the follow-up photographs. RESULTS: Neither sensitivity nor specificity was consistently better for serial stereoscopic photographs than for drawings. Individual ophthalmologist agreement rates with the expert panel's determinations of progression were 23-62% when examiners compared their own drawings to follow-up photographs, 54-71% when examiners compared serial stereoscopic photographs, and 38-85% when comparing another ophthalmologist's drawings to follow-up photographs. CONCLUSION: Baseline stereoscopic photographs of the optic nerve head did not substantially improve recognition of progressive glaucomatous optic nerve damage when compared with the use of baseline drawings of the optic nerve head made from photographs in subjects who developed visual loss in the interim.
Assuntos
Glaucoma/diagnóstico , Disco Óptico/patologia , Nervo Óptico/patologia , Progressão da Doença , Glaucoma/fisiopatologia , Humanos , Variações Dependentes do Observador , Disco Óptico/fisiopatologia , Fotografação , Sensibilidade e EspecificidadeRESUMO
PURPOSE: The Baerveldt glaucoma implant is an aqueous shunting device with large surface area that is installed through a single-quadrant conjunctival incision. A rabbit model of the Baerveldt implant was created to obtain serial histology and clinical information over 1 year. METHODS: Modified versions of the Baerveldt implant (110 or 160 mm2) were implanted in 18 normal New Zealand white rabbit eyes. The rabbits were examined periodically and their intraocular pressures (IOPs) recorded. They were killed at monthly intervals to obtain histology of the bleb capsules. RESULTS: Thin capsules were present at 1 month, which consisted of lamellar collagen deposition surrounded by a granulomatous reaction with multinucleate giant cells. Inflammatory cells (probably macrophages) were scattered on the inner bleb surface. The granulomatous reaction resolved after 4 months. Subsequently, capsule thickness and cellularity remained relatively stable, although the collagen stroma became less compact over time. Sixteen rabbit eyes had initial IOP reductions of > or = 3 mm Hg compared with fellow eyes, which persisted up to 4 weeks postoperatively. Seven eyes (39%) exhibited a hypertensive phase (IOP exceeded that of fellow eye by > or = 3 mm Hg) from 2 weeks to 3 months postoperatively. CONCLUSION: The Baerveldt explant is surrounded by a fibrous capsule that matures over time. The bleb histology in the rabbit model is similar to that described with the Molteno implant in primates and humans, except for the eventual development of a fibroblastic inner lining in the rabbit model. This contrasts with primate and human models, in which the inner lining remains an open mesh.
Assuntos
Tecido Conjuntivo/patologia , Próteses e Implantes , Elastômeros de Silicone , Animais , Humor Aquoso/fisiologia , Colágeno , Túnica Conjuntiva/cirurgia , Drenagem/métodos , Células Gigantes/patologia , Glaucoma/cirurgia , Granuloma/patologia , Pressão Intraocular , Estudos Longitudinais , Macrófagos/patologia , CoelhosRESUMO
BACKGROUND: In order to determine normal outflow facility and aqueous humor production values in Lewis rats, we established methods of measuring aqueous humor dynamics in this animal. METHODS: Outflow facility was determined using anterior chamber infusion with constant pressure. Aqueous humor production was determined by a technique of dilution with FITC-albumin. RESULTS: The mean outflow facility was 0.044 +/- 0.01 microliter/min/mmHg. Rats weighing less than 300 g had lower values than did rats weighing more than 300 g (0.034 +/- 0.006 microliter/min/mmHg vs 0.050 +/- 0.015 microliter/min/mmHg, P = 0.009). The mean aqueous humor production was 0.350 +/- 0.110 microliter/min. The turnover rate of aqueous humor production per minute was 2.23%. CONCLUSIONS: Anterior chamber infusion with constant pressure and the FITC-albumin method allow measurement of the outflow facility and aqueous humor production in Lewis rats. These methods may be useful in assessing aqueous humor dynamics when rats are used as a glaucoma model.
Assuntos
Segmento Anterior do Olho/fisiologia , Humor Aquoso/metabolismo , Animais , Humor Aquoso/citologia , Pressão Intraocular , Aparelho Lacrimal/metabolismo , Tamanho do Órgão , Ratos , Ratos Endogâmicos Lew , Espectrometria de FluorescênciaRESUMO
PURPOSE: To determine if using human cadaveric fascia lata grafts to cover glaucoma implant tubes is safe and effective. METHODS: All patients who underwent glaucoma implant surgery at the Doheny Eye Institute between July 1993 and September 1993 received a fascia lata patch graft to cover the subconjunctival portion of the tube. These patients were followed prospectively for clinical signs of conjunctival breakdown, graft melt, tube erosion, graft-related inflammation, infection, and graft-related complications. RESULTS: Twenty-two eyes of 21 patients were followed for a mean of 19 months. All eyes tolerated the fascia lata grafts well without clinical evidence of graft-related conjunctival, scleral, or intraocular inflammation. No tube erosion or melting of the graft was observed in the study group. CONCLUSION: Preserved donor fascia lata was well tolerated as a grafting material in glaucoma implant surgery. No clinical signs of graft rejection, foreign body reaction, tube erosion, or graft melt were observed in the study group during the follow-up period.
Assuntos
Fascia Lata/transplante , Glaucoma/cirurgia , Implantes de Molteno , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Túnica Conjuntiva/cirurgia , Seguimentos , Humanos , Lactente , Pessoa de Meia-Idade , Complicações Pós-Operatórias , Estudos Prospectivos , Preservação de TecidoRESUMO
BACKGROUND AND OBJECTIVE: To determine the effect of cataract surgery on glaucomatous eyes with good intraocular pressure (IOP) control after trabeculectomy. PATIENTS AND METHODS: Twenty-two eyes with functional blebs that underwent cataract extraction were retrospectively analyzed. RESULTS: The mean (+/- SD) preoperative IOP was 11.0 +/- 4.3 mm Hg. The mean (+/- SD) postoperative IOPs at 1, 2, 6, and 9 months were 15.5 +/- 4.9, 12.6 +/- 4.7, 14.6 +/- 5.6, and 19.0 +/- 7.9 mm Hg, respectively. At each interval except for the second month, the mean IOP was statistically significantly higher than the preoperative value (P = .0003, .24, .02, and .0009, respectively). The total number of medications was also higher (3 preoperatively versus 27 postoperatively). The interval between the two surgeries had no influence on IOP control. Intraoperative complications during cataract surgery, particularly vitreous loss, were associated with poor IOP control. Phacoemulsification had less of an effect on the postoperative IOP control than did extracapsular cataract extraction. CONCLUSIONS: Eyes with previous successful trabeculectomies had higher IOPs and required more medications after subsequent cataract surgeries.
Assuntos
Extração de Catarata , Pressão Intraocular/fisiologia , Trabeculectomia , Idoso , Idoso de 80 Anos ou mais , Catarata/complicações , Catarata/fisiopatologia , Feminino , Seguimentos , Glaucoma de Ângulo Fechado/complicações , Glaucoma de Ângulo Fechado/fisiopatologia , Glaucoma de Ângulo Fechado/cirurgia , Glaucoma de Ângulo Aberto/complicações , Glaucoma de Ângulo Aberto/fisiopatologia , Glaucoma de Ângulo Aberto/cirurgia , Humanos , Masculino , Pessoa de Meia-Idade , Período Pós-Operatório , Estudos Retrospectivos , Fatores de Tempo , Resultado do Tratamento , Acuidade VisualRESUMO
PURPOSE: The objective of this study is to identify the rate and the associated risk factors for suprachoroidal hemorrhage (SCH) after Molteno drain implantation. METHODS: Data from the Molteno pilot study and single versus double-plate Molteno study were reviewed retrospectively for the occurrence of SCH. Follow-up intervals, demographic variables, ocular data, and medical history were collected. RESULTS: SCH occurred in 6% of the patients enrolled in the Molteno studies; all cases were delayed and none were intraoperative. Significantly associated factors in a multiple logistic regression for SCH were the extent of intraocular pressure (IOP) drop after surgery, the post-operative IOP, a diagnosis of angleclosure glaucoma, and possibly the number of prior surgeries as well. Eyes with SCH did significantly less well in terms of visual acuity outcomes and were more likely to have inadequately controlled IOP. CONCLUSIONS: This study suggests that SCH occurs at the same frequency after Molteno implantation as after filtering surgery with antimetabolite use and that eyes with SCH do less well.
Assuntos
Hemorragia da Coroide/etiologia , Glaucoma/cirurgia , Próteses e Implantes/efeitos adversos , Adulto , Idoso , Idoso de 80 Anos ou mais , Hemorragia da Coroide/terapia , Feminino , Glaucoma/fisiopatologia , Humanos , Pressão Intraocular , Masculino , Pessoa de Meia-Idade , Período Pós-Operatório , Fatores de RiscoRESUMO
PURPOSE: The purpose of this study was to assess the effects of intraoperative mitomycin-C (MMC) on the function of Baerveldt glaucoma implants in rabbits. METHODS: Bilateral implantations of 200 mm2 Baerveldt drainage devices were performed in 30 normal albino rabbits. One eye, randomly selected, received intraoperative application of MMC at the site of the implant plate for 5 min, via a 6 x 4 x 2 mm cellulose sponge saturated with 0.5 mg/ml of MMC. The opposite eye served as a control. MMC-treated and control eyes (five animals each group) were compared for intraocular pressure (IOP), resistance to flow, flow rates through the implant and histopathological findings at 2, 4, 6, 12, and 24 weeks postoperatively. Resistance to flow and flow rates through the implants were studied after opening the cornea and connecting the drain tube to a micromanometric system. RESULTS: Preoperative IOP did not differ between groups. MMC-treated eyes had lower levels of IOP than did controls at all postoperative times. The differences in IOP were statistically significant up to 8 weeks postoperatively. Resistance to flow was lower in MMC-treated eyes at all times studied, but the differences were statistically significant only at the time points of 2, 4, and 6 weeks. Flow rates through the implant bleb were always higher in MMC-treated eyes, and statistically significant differences were seen at 2, 4, 6, and 24 weeks. Histopathologically, MMC-treated eyes had thinner implant capsules with delayed maturation and less inflammatory infiltrate. CONCLUSION: MMC causes lower IOP and higher perfusion rates through the implant capsule at 2, 4, and 6 weeks postoperatively. Wound dehiscence, bleb leaks, and extraocular muscle injury were observed only in MMC-treated eyes.
Assuntos
Drenagem/instrumentação , Cirurgia Filtrante , Glaucoma/fisiopatologia , Mitomicina/farmacologia , Inibidores da Síntese de Ácido Nucleico/farmacologia , Próteses e Implantes , Administração Tópica , Animais , Humor Aquoso/metabolismo , Glaucoma/patologia , Glaucoma/cirurgia , Pressão Intraocular/efeitos dos fármacos , Cuidados Intraoperatórios , Músculos Oculomotores/patologia , Coelhos , Distribuição Aleatória , Esclera/ultraestruturaRESUMO
PURPOSE: To evaluate the timing, efficacy, and complications of laser suture lysis (LSL) after mitomycin C trabeculectomy in patients with glaucoma at high risk for failure of filtering surgery. METHODS: The authors retrospectively reviewed the charts of 62 consecutive patients who underwent a total of 66 sessions of LSL after trabeculectomy with mitomycin C. RESULTS: The interval from surgery to LSL ranged from 2 to 65 days (mean +/- standard deviation, 17.9 +/- 14.9 days). The average intraocular pressure (IOP) reduction after LSL was 11.9 +/- 8.9 mmHg (range, 3-40 mmHg). A longer interval to LSL was correlated with a lesser degree of pressure reduction (P=0.0004, Wilcoxon rank-sum test). After LSL, hypotony developed in 13 (21%) patients (IOP < 6 mmHg on 2 consecutive measurements at least 24 hours apart). This resolved spontaneously after 7 to 304 days (104.1 +/- 109.1 days) in 12 (92%) of the 13 patients. Life-table success rates (success defined as 6 mmHg = final IOP = 21 mmHg) for the hypotony and no hypotony groups were 100% and 86% (at 6 months) and 96% and 86% (at 12 months), respectively. The final visual acuity worsened in a significantly greater percentage of patients in the hypotony group (46%) compared with the no-hypotony group (18%) (P = 0.06), Fisher's exact test). CONCLUSIONS: Laser suture lysis is safe and effective in augmenting aqueous filtration after mitomycin C trabeculectomy. A longer time interval between surgery and LSL may result in both a lesser degree of IOP reduction and a lower incidence of subsequent hypotony.
Assuntos
Antibióticos Antineoplásicos/uso terapêutico , Glaucoma/cirurgia , Terapia a Laser , Mitomicina/uso terapêutico , Técnicas de Sutura , Trabeculectomia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Quimioterapia Adjuvante , Criança , Feminino , Glaucoma/tratamento farmacológico , Humanos , Incidência , Pressão Intraocular , Terapia a Laser/efeitos adversos , Tábuas de Vida , Masculino , Pessoa de Meia-Idade , Hipotensão Ocular/etiologia , Hipotensão Ocular/fisiopatologia , Estudos Retrospectivos , Acuidade VisualRESUMO
PURPOSE: The authors present a retrospective study designed to assess the effectiveness of the Baerveldt glaucoma implant in controlling intraocular pressure (IOP) and maintaining visual function in eyes with neovascular glaucoma. METHODS: The medical records of all 36 patients (36 eyes) who underwent Baerveldt glaucoma implantation for medically uncontrolled neovascular glaucoma between February 1991 and December 1992 were reviewed. RESULTS: Eighteen patients received Model 350 implants, 16 received Model 500 implants, and 2 received Model 200 implants. The 12- and 18-month life-table success rates (success defined as 6 mmHg < or = final IOP < or = 21 mmHg without additional glaucoma surgery or devastating complication) were 79% and 56%, respectively. Visual acuity remained stable or improved in 10 (31%) patients. Postoperative complications included flat anterior chamber, serous choroidal detachment, and obstruction of the proximal tube tip with fibrovascular tissue, each of which occurred in four (11%) patients. Eleven (31%) patients lost light perception. There were no significant differences between the groups receiving the Model 350 and Model 500 implants with respect to life-table success rates, percentage of postoperative IOP reduction, or complication rates. Patients in the Model 500 implant group required significantly fewer antiglaucoma medications post-operatively, but also demonstrated a significantly greater mean visual acuity reduction. Better preoperative visual acuity and increased patient age were positively correlated with a successful outcome. CONCLUSIONS: Baerveldt implantation is effective in controlling IOP elevation associated with neovascular glaucoma. Postoperative visual loss, despite adequate IOP control, is common. Young patient age and poorer preoperative visual acuity are significant predictors of surgical failure.
Assuntos
Glaucoma Neovascular/cirurgia , Próteses e Implantes , Adulto , Idoso , Idoso de 80 Anos ou mais , Glaucoma Neovascular/fisiopatologia , Humanos , Pressão Intraocular , Tábuas de Vida , Pessoa de Meia-Idade , Complicações Pós-Operatórias , Estudos Retrospectivos , Resultado do Tratamento , Acuidade VisualRESUMO
PURPOSE: To determine pressure-flow characteristics at physiologic flow rates in vitro and in vivo in rabbits for Ahmed, Baerveldt, Krupin disk, and OptiMed glaucoma implants. The Molteno dual-chamber implant also was evaluated in vivo only. METHODS: Five samples of each glaucoma implant were studied. Baerveldt implants were ligated partially for in vitro testing. Opening and closing pressures in air or after immersion in balanced salt solution or plasma were evaluated for the valved devices (Ahmed and Krupin). Pressures were measured in vitro and in vivo in normal rabbits at flow rates preset at between 2 and 25 microliters/minute after the tubes were connected to a closed manometric system. In vivo measurements were made 24 hours after implantation. Resistance to flow was calculated using Poiseuille's equation after at least three separate flow rate readings. RESULTS: In air, the Ahmed and Krupin valves had opening pressures of 9.2 +/- 3.4 and 7.2 +/- 0.6 mmHg and closing pressures of 5.2 +/- 0.9 and 3.9 +/- 1 mmHg, respectively. Neither opening nor closing pressures could be determined when Ahmed and Krupin valves were immersed. In vitro, the Ahmed and OptiMed devices had higher pressures than did other devices at a 2-microliters/minute flow rate of balanced salt solution. During perfusion with plasma, only the OptiMed device maintained higher pressures than with balanced salt. With all devices, pressures fell rapidly to zero after flow was stopped. The OptiMed device demonstrated the highest resistance values. In vivo, the Ahmed device provided pressures of 7.5 +/- 0.8 mmHg and the OptiMed device gave pressures of 19.6 +/- 5.6 mmHg at a 2-microliters/minute flow rate. After 15 minutes of flow shutdown, the OptiMed implant maintained pressures of 7.1 +/- 1.1 mmHg. The Baerveldt (nonligatured), Krupin, and Molteno dual-chamber implants had similar resistances and pressures in vivo. Pressures with all devices in vivo fell rapidly to zero after conjunctival wound disruption. CONCLUSION: Neither the Ahmed nor Krupin devices had demonstrable opening or closing pressures when tested in vitro immersed in balanced salt solution or plasma. With all devices, pressures were higher in vivo than in vitro due to tissue-induced resistance around the explant. Both Ahmed and Krupin valves functioned as flow-restricting devices at the flow rates studied, but did not close after initial perfusion with fluid.
Assuntos
Humor Aquoso/fisiologia , Drenagem/instrumentação , Glaucoma/fisiopatologia , Próteses e Implantes , Animais , Glaucoma/cirurgia , Técnicas In Vitro , Soluções Isotônicas , Perfusão , Plasma , Pressão , CoelhosRESUMO
PURPOSE: In the preinflammatory phase of S-antigen (S-ag) induced uveitis, an ocular hypotension occurs between day 2 and day 6 after S-ag injection. To better understand this phenomenon, we studied the levels of prostaglandin E2 (PGE2) and prostaglandin F2-alpha (PGF2-alpha) in the aqueous humor of S-ag injected rats at various time points after induction of disease. METHODS: Twenty-five female Lewis rats weighting 150 to 175 gm were injected in the hind foot-pad with 50 micrograms of S-antigen. IOP was measured each day at 9 am with a Tono-Pen tonometer. Aqueous humor was collected at days 0, 2, 4, 6, 9, 14 and 18 after S-ag injection. PGE2 and PGF2-alpha were assayed in the aqueous humor using an enzyme immunoassay method. RESULTS: The concentration of PGE2 increased after day 6 and peaked at day 14 after S-ag injection (45.6 +/- 9.0 mu/ml vs 1.1 +/- 0.1 mu/ml in controls, P = 0.04). The peak of PGE2 corresponded to the maximum inflammation and ocular hypertension. PGF2-alpha was increased from day 2 to day 6, with a peak at day 6 after S-ag injection (128.0 +/- 51 pg/ml vs 56 +/- 2.0 pg/ml in controls, P = 0.047), which corresponded to the preinflammatory ocular hypotension. A second peak was observed at day 18 after S-ag injection (3643 +/- 824 pg/ml, P = 0.049), which corresponded to the cessation of intraocular inflammation and ocular hypertension. CONCLUSIONS: The early increased concentration of PGF2-alpha in the aqueous humor of rats with S-ag induced uveitis may explain the ocular hypotension observed from day 2 to day 6 after S-ag injection.